Lower-risk Myelodysplastic Syndromes: Data Updates and Evolving Treatment Paradigms in the Frontline Setting

Two expert oncologists review the standard-of-care and unmet needs in the treatment of lower-risk Myelodysplastic Syndromes [MDS]. They discuss emerging data on novel therapies and consider their impact on the treatment landscape for patients with lower-risk MDS.

EP. 1: Risk Stratification of Myelodysplastic Syndromes [MDS]

June 15th 2023

Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.

EP. 2: Importance of Early Diagnosis of MDS for Lower and Higher-risk Patients

June 15th 2023

Hetty Carraway, MD, highlights the importance of early diagnosis across all patients with MDS.

EP. 3: Frontline Treatment Options for Lower-Risk MDS

June 22nd 2023

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

EP. 4: Clinical Use of Luspatercept on Patients with Lower-risk MDS

June 22nd 2023

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

EP. 5: Safety and Efficacy of Luspatercept in Frontline Setting in Patients with MDS

June 29th 2023

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

EP. 6: Emerging Therapies for Treatment of MDS

June 29th 2023

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

EP. 7: Clinical Management of Patients with Lower-risk MDS

July 6th 2023

Ralph Boccia, MD, FACP, highlights emerging therapies and the importance of next-generation sequencing for patients with MDS.

EP. 8: Unmet Needs and Future Perspectives in Treatment of MDS

July 6th 2023

Expert oncologists discuss unmet needs and share final thoughts on the future of treatment of patients with lower-risk MDS.